Deborah M. Kurrasch-Orbaugh, Ph.D. - Publications

Purdue University, West Lafayette, IN, United States 
Dopamine and Serotonin Agonists

12 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2006 McLean TH, Chambers JJ, Parrish JC, Braden MR, Marona-Lewicka D, Kurrasch-Orbaugh D, Nichols DE. C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. Journal of Medicinal Chemistry. 49: 4269-74. PMID 16821786 DOI: 10.1021/jm060272y  0.96
2003 Kurrasch-Orbaugh DM, Parrish JC, Watts VJ, Nichols DE. A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases. Journal of Neurochemistry. 86: 980-91. PMID 12887695 DOI: 10.1046/j.1471-4159.2003.01921.x  0.96
2003 Chambers JJ, Parrish JC, Jensen NH, Kurrasch-Orbaugh DM, Marona-Lewicka D, Nichols DE. Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands. Journal of Medicinal Chemistry. 46: 3526-35. PMID 12877591 DOI: 10.1021/jm030064v  0.96
2003 Kurrasch-Orbaugh DM, Watts VJ, Barker EL, Nichols DE. Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. The Journal of Pharmacology and Experimental Therapeutics. 304: 229-37. PMID 12490596 DOI: 10.1124/jpet.102.042184  0.96
2002 Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, Nichols DE. Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats. Psychopharmacology. 164: 93-107. PMID 12373423 DOI: 10.1007/s00213-002-1141-z  0.96
2002 Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). Journal of Medicinal Chemistry. 45: 4344-9. PMID 12213075 DOI: 10.1021/jm020153s  0.96
2002 Whiteside MS, Kurrasch-Orbaugh D, Marona-Lewicka D, Nichols DE, Monte A. Substituted hexahydrobenzodipyrans as 5-HT2A/2C receptor probes. Bioorganic & Medicinal Chemistry. 10: 3301-6. PMID 12150876 DOI: 10.1016/S0968-0896(02)00209-2  0.96
2002 Chambers JJ, Kurrasch-Orbaugh DM, Nichols DE. Translocation of the 5-alkoxy substituent of 2,5-dialkoxyarylalkylamines to the 6-position: effects on 5-HT(2A/2C) receptor affinity. Bioorganic & Medicinal Chemistry Letters. 12: 1997-9. PMID 12113827 DOI: 10.1016/S0960-894X(02)00306-2  0.96
2001 Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, Nichols DE. Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists. Journal of Medicinal Chemistry. 44: 1003-10. PMID 11300881 DOI: 10.1021/jm000491y  0.96
2001 Laban U, Kurrasch-Orbaugh D, Marona-Lewicka D, Nichols DE. A novel fluorinated tryptamine with highly potent serotonin 5-HT1A receptor agonist properties. Bioorganic & Medicinal Chemistry Letters. 11: 793-5. PMID 11277522 DOI: 10.1016/S0960-894X(01)00062-2  1
2000 Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D, Cumbay MG, Watts VJ, Barker EL, Nichols DE. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. Journal of Medicinal Chemistry. 43: 4701-10. PMID 11101361 DOI: 10.1021/jm000339w  0.96
1999 Gerasimov M, Marona-Lewicka D, Kurrasch-Orbaugh DM, Qandil AM, Nichols DE. Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain. Journal of Medicinal Chemistry. 42: 4257-63. PMID 10514296 DOI: 10.1021/jm990325u  0.96
Show low-probability matches.